These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

100 related items for PubMed ID: 17848408

  • 1. Bcl-2 overexpression in thyroid carcinoma cells increases sensitivity to Bcl-2 homology 3 domain inhibition.
    Mitsiades CS, Hayden P, Kotoula V, McMillin DW, McMullan C, Negri J, Delmore JE, Poulaki V, Mitsiades N.
    J Clin Endocrinol Metab; 2007 Dec; 92(12):4845-52. PubMed ID: 17848408
    [Abstract] [Full Text] [Related]

  • 2. Antitumor effects of the proteasome inhibitor bortezomib in medullary and anaplastic thyroid carcinoma cells in vitro.
    Mitsiades CS, McMillin D, Kotoula V, Poulaki V, McMullan C, Negri J, Fanourakis G, Tseleni-Balafouta S, Ain KB, Mitsiades N.
    J Clin Endocrinol Metab; 2006 Oct; 91(10):4013-21. PubMed ID: 16849420
    [Abstract] [Full Text] [Related]

  • 3. Bik/NBK accumulation correlates with apoptosis-induction by bortezomib (PS-341, Velcade) and other proteasome inhibitors.
    Zhu H, Zhang L, Dong F, Guo W, Wu S, Teraishi F, Davis JJ, Chiao PJ, Fang B.
    Oncogene; 2005 Jul 21; 24(31):4993-9. PubMed ID: 15824729
    [Abstract] [Full Text] [Related]

  • 4. The proteasome inhibitor bortezomib sensitizes cells to killing by death receptor ligand TRAIL via BH3-only proteins Bik and Bim.
    Nikrad M, Johnson T, Puthalalath H, Coultas L, Adams J, Kraft AS.
    Mol Cancer Ther; 2005 Mar 21; 4(3):443-9. PubMed ID: 15767553
    [Abstract] [Full Text] [Related]

  • 5. Synergistic induction of oxidative injury and apoptosis in human multiple myeloma cells by the proteasome inhibitor bortezomib and histone deacetylase inhibitors.
    Pei XY, Dai Y, Grant S.
    Clin Cancer Res; 2004 Jun 01; 10(11):3839-52. PubMed ID: 15173093
    [Abstract] [Full Text] [Related]

  • 6. The proteasome inhibitor bortezomib induces apoptosis in human retinoblastoma cell lines in vitro.
    Poulaki V, Mitsiades CS, Kotoula V, Negri J, McMillin D, Miller JW, Mitsiades N.
    Invest Ophthalmol Vis Sci; 2007 Oct 01; 48(10):4706-19. PubMed ID: 17898295
    [Abstract] [Full Text] [Related]

  • 7. Proteasome inhibitors synergize with tumor necrosis factor-related apoptosis-induced ligand to induce anaplastic thyroid carcinoma cell death.
    Conticello C, Adamo L, Giuffrida R, Vicari L, Zeuner A, Eramo A, Anastasi G, Memeo L, Giuffrida D, Iannolo G, Gulisano M, De Maria R.
    J Clin Endocrinol Metab; 2007 May 01; 92(5):1938-42. PubMed ID: 17327374
    [Abstract] [Full Text] [Related]

  • 8. Cooperative cytotoxicity of proteasome inhibitors and tumor necrosis factor-related apoptosis-inducing ligand in chemoresistant Bcl-2-overexpressing cells.
    Nencioni A, Wille L, Dal Bello G, Boy D, Cirmena G, Wesselborg S, Belka C, Brossart P, Patrone F, Ballestrero A.
    Clin Cancer Res; 2005 Jun 01; 11(11):4259-65. PubMed ID: 15930365
    [Abstract] [Full Text] [Related]

  • 9. Molecular sequelae of proteasome inhibition in human multiple myeloma cells.
    Mitsiades N, Mitsiades CS, Poulaki V, Chauhan D, Fanourakis G, Gu X, Bailey C, Joseph M, Libermann TA, Treon SP, Munshi NC, Richardson PG, Hideshima T, Anderson KC.
    Proc Natl Acad Sci U S A; 2002 Oct 29; 99(22):14374-9. PubMed ID: 12391322
    [Abstract] [Full Text] [Related]

  • 10. Differential regulation of noxa in normal melanocytes and melanoma cells by proteasome inhibition: therapeutic implications.
    Fernández Y, Verhaegen M, Miller TP, Rush JL, Steiner P, Opipari AW, Lowe SW, Soengas MS.
    Cancer Res; 2005 Jul 15; 65(14):6294-304. PubMed ID: 16024631
    [Abstract] [Full Text] [Related]

  • 11. A pivotal role for Mcl-1 in Bortezomib-induced apoptosis.
    Podar K, Gouill SL, Zhang J, Opferman JT, Zorn E, Tai YT, Hideshima T, Amiot M, Chauhan D, Harousseau JL, Anderson KC.
    Oncogene; 2008 Jan 31; 27(6):721-31. PubMed ID: 17653083
    [Abstract] [Full Text] [Related]

  • 12. Histone deacetylase inhibitor depsipeptide (FK228) induces apoptosis in leukemic cells by facilitating mitochondrial translocation of Bax, which is enhanced by the proteasome inhibitor bortezomib.
    Sutheesophon K, Kobayashi Y, Takatoku MA, Ozawa K, Kano Y, Ishii H, Furukawa Y.
    Acta Haematol; 2006 Jan 31; 115(1-2):78-90. PubMed ID: 16424655
    [Abstract] [Full Text] [Related]

  • 13. Enhanced killing of melanoma cells by simultaneously targeting Mcl-1 and NOXA.
    Qin JZ, Xin H, Sitailo LA, Denning MF, Nickoloff BJ.
    Cancer Res; 2006 Oct 01; 66(19):9636-45. PubMed ID: 17018621
    [Abstract] [Full Text] [Related]

  • 14. Targeting the proteasome as a promising therapeutic strategy in thyroid cancer.
    Wunderlich A, Arndt T, Fischer M, Roth S, Ramaswamy A, Greene BH, Brendel C, Hinterseher U, Bartsch DK, Hoffmann S.
    J Surg Oncol; 2012 Mar 15; 105(4):357-64. PubMed ID: 22006286
    [Abstract] [Full Text] [Related]

  • 15. SIN1, a critical component of the mTOR-Rictor complex, is overexpressed and associated with AKT activation in medullary and aggressive papillary thyroid carcinomas.
    Moraitis D, Karanikou M, Liakou C, Dimas K, Tzimas G, Tseleni-Balafouta S, Patsouris E, Rassidakis GZ, Kouvaraki MA.
    Surgery; 2014 Dec 15; 156(6):1542-8; discussion 1548-9. PubMed ID: 25456951
    [Abstract] [Full Text] [Related]

  • 16. Bortezomib primes glioblastoma, including glioblastoma stem cells, for TRAIL by increasing tBid stability and mitochondrial apoptosis.
    Unterkircher T, Cristofanon S, Vellanki SH, Nonnenmacher L, Karpel-Massler G, Wirtz CR, Debatin KM, Fulda S.
    Clin Cancer Res; 2011 Jun 15; 17(12):4019-30. PubMed ID: 21525171
    [Abstract] [Full Text] [Related]

  • 17. Noxa up-regulation and Mcl-1 cleavage are associated to apoptosis induction by bortezomib in multiple myeloma.
    Gomez-Bougie P, Wuillème-Toumi S, Ménoret E, Trichet V, Robillard N, Philippe M, Bataille R, Amiot M.
    Cancer Res; 2007 Jun 01; 67(11):5418-24. PubMed ID: 17545623
    [Abstract] [Full Text] [Related]

  • 18. BCL-2 phosphorylation modulates sensitivity to the BH3 mimetic GX15-070 (Obatoclax) and reduces its synergistic interaction with bortezomib in chronic lymphocytic leukemia cells.
    Pérez-Galán P, Roué G, López-Guerra M, Nguyen M, Villamor N, Montserrat E, Shore GC, Campo E, Colomer D.
    Leukemia; 2008 Sep 01; 22(9):1712-20. PubMed ID: 18596739
    [Abstract] [Full Text] [Related]

  • 19. Antitumor effects of proteasome inhibition in anaplastic thyroid carcinoma.
    Altmann A, Markert A, Askoxylakis V, Schöning T, Jesenofsky R, Eisenhut M, Haberkorn U.
    J Nucl Med; 2012 Nov 01; 53(11):1764-71. PubMed ID: 23055533
    [Abstract] [Full Text] [Related]

  • 20. The proteasome inhibitor PS-341 (bortezomib) up-regulates DR5 expression leading to induction of apoptosis and enhancement of TRAIL-induced apoptosis despite up-regulation of c-FLIP and survivin expression in human NSCLC cells.
    Liu X, Yue P, Chen S, Hu L, Lonial S, Khuri FR, Sun SY.
    Cancer Res; 2007 May 15; 67(10):4981-8. PubMed ID: 17510429
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 5.